Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07082803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions modified Eligibility criteria shortened, about 9 words · Site contacts updated at 2 of 14 sitesv12 Show 2 more changesShow less
    • Eligibility criteria shortened, about 9 words
    • Site contacts updated at 2 of 14 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 13 to 14v11
  3. Study sites: 12 to 13v10
  4. Study sites: 11 to 12v9
  5. Study sites: 10 to 11v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites revised (10)v7 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 9 to 10 Eligibility criteria expanded, about 38 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 38 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 8 to 9v5
  4. Re-verified, no change to tracked fieldsv4
  5. Study sites: 7 to 8v3
  6. Study sites: 2 to 7 Study title shortened, about 5 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Trial Details
NCT Number NCT07082803
Lead Sponsor Treeline Biosciences, Inc.
Conditions Lymphoma, Lymphoma, Non Hodgkin
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov